Amoneta Diagnostics
Description: Bienvenue sur le site de Amoneta Diagnostics, Huningue
conseil (4153) offre (1555) compétence (1481)
With an ultimate aim to develop and market a fast, reliable and non-invasive peripheral blood diagnostic kit for Alzheimer's Disease (AD), the ADDIA consortium is aiming to perform a clinical validation study.
Validating the performance of the ADDIA biomarkers in relation to the Alzheimer's Disease progression in a multicentre Proof of Performance (PoP) study and registering the ADDIA kit as an "in-vitro diagnostic" (IVD) product for marketing are the two main scientific and commercial objectives of the project.
Amoneta Diagnostics has previously developed a diagnostic kit (ADDIA kit) for Alzheimer’s disease (AD), based on a detection of two complementary blood biomarkers that are scientifically proven to be associated with Alzheimer's Disease and already shown to be highly sensitive and specific for the diagnosis of AD in a small-scale human clinical study.
Amoneta Diagnostics